Trial Profile

PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Irinotecan (Primary) ; Palbociclib (Primary) ; Palbociclib (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
Indications CNS cancer; Diffuse intrinsic pontine glioma; Ewing's sarcoma; Glioma; Medulloblastoma; Neuroblastoma; Rhabdoid tumour; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

11 Sep 2024 Planned End Date changed from 25 Feb 2025 to 18 Oct 2025.
17 Jun 2024 Planned primary completion date changed from 24 Aug 2024 to 19 Aug 2024.
29 Feb 2024 Planned primary completion date changed from 30 Aug 2024 to 24 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com